These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 27809361)
21. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764 [TBL] [Abstract][Full Text] [Related]
22. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells. Chen YH; Lv H; Shen N; Wang XM; Tang S; Xiong B; Ding J; Geng MY; Huang M Acta Pharmacol Sin; 2020 Feb; 41(2):270-277. PubMed ID: 31316177 [TBL] [Abstract][Full Text] [Related]
23. Assay and functional properties of PrBP(PDEdelta), a prenyl-binding protein interacting with multiple partners. Zhang H; Hosier S; Terew JM; Zhang K; Cote RH; Baehr W Methods Enzymol; 2005; 403():42-56. PubMed ID: 16473576 [TBL] [Abstract][Full Text] [Related]
24. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design. Chen L; Zhuang C; Lu J; Jiang Y; Sheng C J Med Chem; 2018 Mar; 61(6):2604-2610. PubMed ID: 29510040 [TBL] [Abstract][Full Text] [Related]
25. Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism. Winzker M; Friese A; Koch U; Janning P; Ziegler S; Waldmann H Angew Chem Int Ed Engl; 2020 Mar; 59(14):5595-5601. PubMed ID: 31829492 [TBL] [Abstract][Full Text] [Related]
26. Identification of novel PDEδ interacting proteins. Küchler P; Zimmermann G; Winzker M; Janning P; Waldmann H; Ziegler S Bioorg Med Chem; 2018 May; 26(8):1426-1434. PubMed ID: 28935183 [TBL] [Abstract][Full Text] [Related]
27. Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors. Salmas RE; Mestanoglu M; Yurtsever M; Noskov SY; Durdagi S Biophys J; 2015 Sep; 109(6):1163-8. PubMed ID: 26340817 [TBL] [Abstract][Full Text] [Related]
28. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer. Cheng J; Li Y; Wang X; Dong G; Sheng C J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594 [TBL] [Abstract][Full Text] [Related]
30. Mapping the isoprenoid binding pocket of PDEdelta by a semisynthetic, photoactivatable N-Ras lipoprotein. Alexander M; Gerauer M; Pechlivanis M; Popkirova B; Dvorsky R; Brunsveld L; Waldmann H; Kuhlmann J Chembiochem; 2009 Jan; 10(1):98-108. PubMed ID: 18846587 [TBL] [Abstract][Full Text] [Related]
31. Regulation of K-Ras4B Membrane Binding by Calmodulin. Sperlich B; Kapoor S; Waldmann H; Winter R; Weise K Biophys J; 2016 Jul; 111(1):113-22. PubMed ID: 27410739 [TBL] [Abstract][Full Text] [Related]
32. PDE6D Inhibitors with a New Design Principle Selectively Block K-Ras Activity. Siddiqui FA; Alam C; Rosenqvist P; Ora M; Sabt A; Manoharan GB; Bindu L; Okutachi S; Catillon M; Taylor T; Abdelhafez OM; Lönnberg H; Stephen AG; Papageorgiou AC; Virta P; Abankwa D ACS Omega; 2020 Jan; 5(1):832-842. PubMed ID: 31956834 [TBL] [Abstract][Full Text] [Related]
33. The interplay between RPGR, PDEδ and Arl2/3 regulate the ciliary targeting of farnesylated cargo. Wätzlich D; Vetter I; Gotthardt K; Miertzschke M; Chen YX; Wittinghofer A; Ismail S EMBO Rep; 2013 May; 14(5):465-72. PubMed ID: 23559067 [TBL] [Abstract][Full Text] [Related]
34. Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. Ismail SA; Chen YX; Rusinova A; Chandra A; Bierbaum M; Gremer L; Triola G; Waldmann H; Bastiaens PI; Wittinghofer A Nat Chem Biol; 2011 Oct; 7(12):942-9. PubMed ID: 22002721 [TBL] [Abstract][Full Text] [Related]
35. An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review. Sabt A; Tawfik HO; Khaleel EF; Badi RM; Ibrahim HAA; Elkaeed EB; Eldehna WM Mol Divers; 2024 Dec; 28(6):4581-4608. PubMed ID: 38289431 [TBL] [Abstract][Full Text] [Related]
36. Targeting the K-Ras/PDEδ protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage? Frett B; Wang Y; Li HY ChemMedChem; 2013 Oct; 8(10):1620-2. PubMed ID: 23939923 [TBL] [Abstract][Full Text] [Related]
37. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Hunter JC; Gurbani D; Ficarro SB; Carrasco MA; Lim SM; Choi HG; Xie T; Marto JA; Chen Z; Gray NS; Westover KD Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8895-900. PubMed ID: 24889603 [TBL] [Abstract][Full Text] [Related]
38. Discovery of Novel PDEδ Autophagic Degraders: A Case Study of Autophagy-Tethering Compound (ATTEC). Bao J; Chen Z; Li Y; Chen L; Wang W; Sheng C; Dong G ACS Med Chem Lett; 2024 Jan; 15(1):29-35. PubMed ID: 38229750 [TBL] [Abstract][Full Text] [Related]
39. Structural Biology-Inspired Discovery of Novel KRAS-PDEδ Inhibitors. Jiang Y; Zhuang C; Chen L; Lu J; Dong G; Miao Z; Zhang W; Li J; Sheng C J Med Chem; 2017 Nov; 60(22):9400-9406. PubMed ID: 28929751 [TBL] [Abstract][Full Text] [Related]